{"title":"炎症性肠病药物治疗的新进展。","authors":"J W Harting","doi":"10.1007/BF01962550","DOIUrl":null,"url":null,"abstract":"<p><p>In this article the clinical features and aetiology of inflammatory bowel diseases are described and current pharmacotherapeutic possibilities are explored. Also reviewed are recent developments and future prospects for the pharmacotherapy of inflammatory bowel diseases, including aminosalicylates, corticosteroids, immunosuppressants, lipoxygenase inhibitors, fish oil, sucralfate, bismuth compounds, free radical scavengers, (hydroxy)chloroquine, sodium cromoglycate and methotrexate.</p>","PeriodicalId":19804,"journal":{"name":"Pharmaceutisch weekblad. Scientific edition","volume":"14 4A","pages":"275-86"},"PeriodicalIF":0.0000,"publicationDate":"1992-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF01962550","citationCount":"4","resultStr":"{\"title\":\"New developments in the pharmacotherapy of inflammatory bowel disease.\",\"authors\":\"J W Harting\",\"doi\":\"10.1007/BF01962550\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this article the clinical features and aetiology of inflammatory bowel diseases are described and current pharmacotherapeutic possibilities are explored. Also reviewed are recent developments and future prospects for the pharmacotherapy of inflammatory bowel diseases, including aminosalicylates, corticosteroids, immunosuppressants, lipoxygenase inhibitors, fish oil, sucralfate, bismuth compounds, free radical scavengers, (hydroxy)chloroquine, sodium cromoglycate and methotrexate.</p>\",\"PeriodicalId\":19804,\"journal\":{\"name\":\"Pharmaceutisch weekblad. Scientific edition\",\"volume\":\"14 4A\",\"pages\":\"275-86\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/BF01962550\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmaceutisch weekblad. Scientific edition\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/BF01962550\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutisch weekblad. Scientific edition","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF01962550","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
New developments in the pharmacotherapy of inflammatory bowel disease.
In this article the clinical features and aetiology of inflammatory bowel diseases are described and current pharmacotherapeutic possibilities are explored. Also reviewed are recent developments and future prospects for the pharmacotherapy of inflammatory bowel diseases, including aminosalicylates, corticosteroids, immunosuppressants, lipoxygenase inhibitors, fish oil, sucralfate, bismuth compounds, free radical scavengers, (hydroxy)chloroquine, sodium cromoglycate and methotrexate.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
